Estimates of progression-free survival (IMAGE)
Caption
In the overall study population, the median progression-free survival (PFS) in the combination therapy group was 18.2 months (95% CI: 11.9–31.1). This result highlights the effectiveness of pyrotinib and fulvestrant in controlling tumor progression in the challenging context of HR+/HER2+ metastatic breast cancer. Notably, the median PFS for patients receiving the combination as first-line therapy was 19.5 months, demonstrating robust efficacy in those undergoing initial treatment. Furthermore, for patients with brain metastases, the median PFS was 18.4 months, surpassing the limitations of traditional therapies in crossing the blood-brain barrier and underscoring the potential efficacy of pyrotinib in targeting the central nervous system.
Credit
Ying Wang
Usage Restrictions
Please cite source
License
Original content